Tenax Therapeutics (NASDAQ:TENX) Now Covered by Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report released on Tuesday, MarketBeat reports. The firm issued an overweight rating and a $35.00 target price on the specialty pharmaceutical company’s stock.

Several other research firms also recently weighed in on TENX. Guggenheim raised their price objective on Tenax Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research note on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Monday, December 22nd. Lifesci Capital raised Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, March 12th. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $29.67.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $15.17 on Tuesday. Tenax Therapeutics has a one year low of $4.63 and a one year high of $18.38. The firm has a market capitalization of $94.66 million, a P/E ratio of -11.41 and a beta of 1.41. The company’s fifty day moving average is $13.42 and its two-hundred day moving average is $10.13.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.88. On average, sell-side analysts forecast that Tenax Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in Tenax Therapeutics during the 3rd quarter valued at $92,000. Letko Brosseau & Associates Inc. purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at $130,000. Corient Private Wealth LLC purchased a new stake in shares of Tenax Therapeutics in the fourth quarter valued at $151,000. Quadrature Capital Ltd acquired a new stake in shares of Tenax Therapeutics during the fourth quarter valued at $252,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Tenax Therapeutics during the fourth quarter valued at $273,000. 1.67% of the stock is currently owned by institutional investors and hedge funds.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.